Renal Function Outcomes in De Novo Kidney Transplant Recipients Receiving Everolimus with Reduced-Exposure Calcineurin Inhibitor versus Mycophenolate with Standard-Exposure Calcineurin Inhibitor: Results from the TRANSFORM Study

被引：1

作者：

Oppenheimer, Federico ^{[1
]}

Russ, Graeme ^{[2
]}

Viklicky, Ondrej ^{[3
]}

Oberbauer, Rainer ^{[4
]}

Garcia, Valter ^{[5
]}

Witzke, Oliver ^{[6
]}

Kuypers, Dirk ^{[7
]}

Danguilan, Romina ^{[8
]}

Das Gupta, Ayan ^{[9
]}

Bernhardt, Peter ^{[10
]}

Sommerer, Claudia ^{[11
]}

机构：

[1] Hosp Clin Barcelona, Barcelona, Spain

[2] Royal Adelaide Hosp, Adelaide, SA, Australia

[3] IKEM, Prague, Czech Republic

[4] Med Univ Vienna, Vienna, Austria

[5] Santa Casa Misericordia Porto Alegre, Porto Alegre, RS, Brazil

[6] Univ Klinikum Essen, Essen, Germany

[7] Gasthuisberg Univ Hosp, Leuven, Belgium

[8] Natl Kidney & Transplant Inst, Quezon City, Philippines

[9] Novartis Healthcare Pvt Ltd, Hyderabad, India

[10] Novartis Pharma AG, Basel, Switzerland

[11] Univ Klinikum Heidelberg, Heidelberg, Germany

来源：

TRANSPLANTATION | 2018年 / 102卷

关键词：

D O I：

10.1097/01.tp.0000543112.91427.9d

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

591.2

引用

页码：S363 / S363

页数：1

共 50 条

[21] EFFECT OF INDUCTION THERAPY ON OUTCOMES OF DE NOVO RENAL TRANSPLANT RECIPIENTS RECEIVING EVEROLIMUS WITH REDUCED-DOSE CALCINEURIN INHIBITOR: 24-MONTH RESULTS FROM TRANSFORM STUDY
Pernin, V.
Legendre, C.
Buchler, M.
Oberbauer, R.
Vincenti, F.
Viklicky, O.
Huynh-Do, U.
Kim, D.
Narvekar, P.
Hernandez-Gutierrez, M. P.
Bernhardt, P.
Gharbi, H.
Kuypers, D.
TRANSPLANT INTERNATIONAL, 2020, 33 : 12 - 12
[22] THE TRANSFORM STUDY: 12-MONTH EFFICACY AND SAFETY OF EVEROLIMUS WITH REDUCED CALCINEURIN INHIBITOR IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS
Pascual, Julio
Berger, Stefan
Witzke, Oliver
Chadban, Steve
Oppenheimer, Federico
Oberbauer, Rainer
Watarai, Yoshihiko
Legendre, Christophe
Luo, Wen-Lin
Marti, Anamaria
Bernhardt, Peter
Tedesco, Helio
TRANSPLANT INTERNATIONAL, 2017, 30 : 159 - 159
[23] Cardiovascular Outcomes in De Novo Kidney Transplant Recipients Receiving Everolimus and Reduced Calcineurin Inhibitor or Standard Triple Therapy: 24-month Post Hoc Analysis From TRANSFORM Study
Sommerer, Claudia
Legendre, Christophe
Citterio, Franco
Watarai, Yoshihiko
Oberbauer, Rainer
Basic-Jukic, Nikolina
Han, Jackie
Gawai, Apurva
Bernhardt, Peter
Chadban, Steve
TRANSPLANTATION, 2023, 107 (07) : 1593 - 1604
[24] Effect of Induction Therapy on Outcomes of De Novo Renal Transplant Recipients Receiving Everolimus with Reduced-Dose Calcineurin Inhibitor: 24-Month Results from the TRANSFORM Study.
Oberbauer, R.
Vincenti, F.
Viklicky, O.
Huynh-Do, U.
Kim, D.
Cruzado, J. M.
Qazi, Y.
Kim, M. S.
Narvekar, P.
Gutierrez, M. P. Hernandez
Bernhardt, P.
Kuypers, D.
AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 558 - 558
[25] Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study
Berger, Stefan P.
Sommerer, Claudia
Witzke, Oliver
Tedesco, Helio
Chadban, Steve
Mulgaonkar, Shamkant
Qazi, Yasir
de Fijter, Johan W.
Oppenheimer, Federico
Cruzado, Josep M.
Watarai, Yoshihiko
Massari, Pablo
Legendre, Christophe
Citterio, Franco
Henry, Mitchell
Srinivas, Titte R.
Vincenti, Flavio
Gutierrez, Maria Pilar Hernandez
Marti, Ana Maria
Bernhardt, Peter
Pascual, Julio
AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 (11) : 3018 - 3034
[26] TRANSFORM: Everolimus with reduced calcineurin inhibitors vs mycophenolate with standard calcineurin inhibitors in de novo kidney transplant recipients - baseline data according to donor type
Watarai, Yoshihiko
Berger, Stefan P.
TRANSPLANTATION, 2016, 100 (07) : S673 - S674
[27] EFFICACY AND SAFETY OF EVEROLIMUS WITH REDUCED CALCINEURIN INHIBITOR REGIMEN VERSUS MYCOPHENOLIC ACID WITH STANDARD CALCINEURIN REGIMEN IN ASIAN DE NOVO KIDNEY TRANSPLANT RECIPIENTS: TWO-YEAR RESULTS FROM THE SUBGROUP ANALYSIS OF TRANSFORM STUDY
Watarai, Yoshihiko
Amante, Angel Joaquin
Casasola, Concesa
Kim, Myoung Soo
Chang, Shen-Shin
Han, Duck Jong
Ingsathit, Atiporn
Kee, Terence
Kenmochi, Takashi
Khullar, Dinesh
Ruangkanchanasetr, Prajej
Shu, Kuo-Hsiung
Wong, Hin Seng
Gawai, Apurva
Hernandez-Gutierrez, Maria Pilar
Danguilan, Romina
TRANSPLANTATION, 2020, 104 (09) : S613 - S613
[28] Results of a 12-month, multicenter, randomized trial of everolimus with reduced-exposure cyclosporine versus MMF and standard-exposure cyclosporine in De Novo cardiac transplant recipients
Lebmkuhl, H.
Livi, U.
Arizon, J.
Vigano, M.
Magelli, C.
Boissonnat, P.
Gerosa, G.
Musumeci, F.
Gandjbakhch, I.
Vanhaecke, J.
Hexham, J. M.
Mange, K. C.
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2008, 27 (02): : S65 - S65
[29] Efficacy and Safety Outcomes by Donor Type in De Novo Renal Transplant Recipients Receiving Everolimus with Reduced-Dose Calcineurin Inhibitor: 24-Month Results from Transform
Berger, S.
Bakr, M.
Bemelman, F.
Danguilan, R.
De Fijter, H.
Han, D.
Kim, M.
Mor, E.
Patel, A.
Gutierrez, M. Hernandez
Gawai, A.
Watarai, Y.
AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 942 - 943
[30] Everolimus with reduced-exposure cyclosporine versus MMF and standard-exposure cyclosporine in de novo cardiac transplant recipients: 12-month results from a multicenter, Randomized trial
Arizon, Jose
Lehmkuhl, Hans
Livi, Ugolino
Vigano, Mario
Branzi, Angelo
Almenar, Luis
Gerosa, Gino
Musumeci, Francesco
Vamous, Shaida
Maccherini, Massimo
Hexham, Mark
Mange, Kevin C.
AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 : 211 - 211

← 1 2 3 4 5 →